Schwarz files Parkinson’s patch
This article was originally published in Pharmaceutical Approvals Monthly
Schwarz' Sept. 29 submission of Neupro (rotigotine) for treatment of early-stage Parkinson's disease is the generic firm's first attempt at the new drug market. The transdermal rotigotine patch is "the first submission of a novel new chemical entity from our…pipeline," the company says. Rotigotine is a non-ergot dopamine D2 agonist; Schwarz licensed the product from Aderis in 1998. Phase III studies in late-stage PD are ongoing, with an NDA projected for first-quarter 2006. A nasal spray rotigotine formulation is in Phase I studies for acute PD...
You may also be interested in...
Data show Opdivo/Cabometyx combo bests Sutent for overall and progression-free survival and response endpoints in first-line RCC. Exelixis CEO says comparison to Sutent is standard control and allows better comparison to other combo regimens.
ES: Public Company Edition: Fifty biopharma companies launched initial public offerings in the US last year and there have been 52 so far in 2020, including Metacrine, Dyne, Athira and COMPASS.
In an update to stakeholders, the US FDA says regulators can successfully evaluate a firm’s performance, allowing it to eventually get medical software to market in the agency’s Pre-Cert Program.